Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Zepbound (autoinjector)

Tirzepatide

RLDNDA 217806 6 strengths Eli Lilly And Co
Approved
Nov 08, 2023
Strengths
6
Listed patents
8

What does the FDA Orange Book show for Zepbound (autoinjector)?

Zepbound (autoinjector) contains Tirzepatide and is the new drug FDA Orange Book record for NDA 217806. The application has 6 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 217806

New drug application identity from the Orange Book snapshot.

Application holder
Eli Lilly And Co

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
6

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
8

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
4

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0012.5MG/0.5ML (2.5MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS
0025MG/0.5ML (5MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS
0037.5MG/0.5ML (7.5MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS
00410MG/0.5ML (10MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS
00512.5MG/0.5ML (12.5MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS
00615MG/0.5ML (15MG/0.5ML)SOLUTIONSUBCUTANEOUSPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Eli Lilly And Co

The Orange Book identifies this organization as the applicant responsible for NDA 217806.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

6 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

8 listed patent expirations and 4 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jul 22, 2039. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 1 other NDA found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 217806 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Solution · Subcutaneous

Tirzepatide

2 applications
Product rows
48
Active applications
2
Active with AB row
0
Mounjaro · NDA 215866

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-217806

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

6 approved presentations · NDA 217806
RLDRS
Strength
2.5MG/0.5ML (2.5MG/0.5ML)
Dosage form
SOLUTION
Route
SUBCUTANEOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    2 yr 9 mo ago

  2. Today

  3. Exclusivity ends · NP

    New product exclusivity (3 years)

    in 4 mo

  4. Exclusivity ends · NCE

    New chemical entity exclusivity (5 years)

    in 10 mo

  5. Exclusivity ends · M-82

    New use / labeling-change exclusivity (3 years)

    in 1 yr 3 mo

  6. Exclusivity ends · I-958

    New indication exclusivity (3 years)

    in 1 yr 5 mo

  7. Patent 9474780 expires

    Listed drug substance patent expiration.

    in 9 yr 7 mo

  8. Patent 11357820 expires

    Listed drug product patent expiration.

    in 13 yr 1 mo

  9. Patent 11918623 expires

    Listed method-of-use patent (U-3855) expiration.

    in 13 yr 1 mo

  10. Patent 12453756 expires

    Listed drug product patent expiration.

    in 13 yr 1 mo

  11. Patent 12629404 expires

    Listed drug product patent expiration.

    in 13 yr 1 mo

  12. Patent 12629404 expires

    Listed drug product patent expiration.

    in 13 yr 1 mo

  13. Patent 12343382 expires

    Listed method-of-use patent (U-4228) expiration.

    in 13 yr 2 mo

  14. Patent 12343382 expires

    Listed method-of-use patent (U-4227) expiration.

    in 13 yr 2 mo

  15. Patent 12343382 expires

    Listed method-of-use patent (U-4409) expiration.

    in 13 yr 2 mo

  16. Patent 12343382 expires

    Listed method-of-use patent (U-4410) expiration.

    in 13 yr 2 mo

  17. Patent 12453758 expires

    Listed method-of-use patent (U-4308) expiration.

    in 13 yr 2 mo

  18. Patent 12453758 expires

    Listed method-of-use patent (U-4311) expiration.

    in 13 yr 2 mo

  19. Patent 12453758 expires

    Listed method-of-use patent (U-4310) expiration.

    in 13 yr 2 mo

  20. Patent 12453758 expires

    Listed method-of-use patent (U-4309) expiration.

    in 13 yr 2 mo

  21. Patent 12616740 expires

    Listed method-of-use patent (U-4497) expiration.

    in 13 yr 2 mo

  22. Patent 12616740 expires

    Listed method-of-use patent (U-4498) expiration.

    in 13 yr 2 mo

  23. Patent 12616740 expires

    Listed method-of-use patent (U-4499) expiration.

    in 13 yr 2 mo

Patent & exclusivity timeline

Protection horizon
20262028203020322034203620382040TodayExclusivity NP: 2026-11-08Exclusivity NPExclusivity NCE: 2027-05-13Exclusivity NCEExclusivity M-82: 2027-10-18Exclusivity M-82Exclusivity I-958: 2027-12-20Exclusivity I-958Patent 9474780: 2036-01-05Patent 9474780Patent 11357820: 2039-06-14Patent 11357820Patent 11918623: 2039-06-14Patent 11918623Patent 12453756: 2039-06-14Patent 12453756Patent 12629404: 2039-06-14Patent 12629404Patent 12629404: 2039-06-14Patent 12629404Patent 12343382: 2039-07-22Patent 12343382Patent 12343382: 2039-07-22Patent 12343382Patent 12343382: 2039-07-22Patent 12343382Patent 12343382: 2039-07-22Patent 12343382Patent 12453758: 2039-07-22Patent 12453758Patent 12453758: 2039-07-22Patent 12453758Patent 12453758: 2039-07-22Patent 12453758Patent 12453758: 2039-07-22Patent 12453758Patent 12616740: 2039-07-22Patent 12616740Patent 12616740: 2039-07-22Patent 12616740Patent 12616740: 2039-07-22Patent 12616740
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

TIRZEPATIDE

Strength

2.5MG/0.5ML (2.5MG/0.5ML)

Dosage form

SOLUTION

Route

SUBCUTANEOUS

TE code

Not listed

Application

NDA 217806

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Marketing exclusivity

Hatch-Waxman
  • NPNew product exclusivity (3 years)

    in 4 mo

  • NCENew chemical entity exclusivity (5 years)

    in 10 mo

  • M-82New use / labeling-change exclusivity (3 years)

    in 1 yr 3 mo

  • I-958New indication exclusivity (3 years)

    in 1 yr 5 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9474780in 9 yr 7 mo
SubstanceProduct
11357820in 13 yr 1 mo
Product
11918623in 13 yr 1 mo
U-3855
12453756in 13 yr 1 mo
Product
12629404in 13 yr 1 mo
ProductU-4531
12629404in 13 yr 1 mo
ProductU-4532
12343382in 13 yr 2 mo
U-4228
12343382in 13 yr 2 mo
U-4227
12343382in 13 yr 2 mo
U-4409
12343382in 13 yr 2 mo
U-4410
12453758in 13 yr 2 mo
U-4308
12453758in 13 yr 2 mo
U-4311
12453758in 13 yr 2 mo
U-4310
12453758in 13 yr 2 mo
U-4309
12616740in 13 yr 2 mo
U-4497
12616740in 13 yr 2 mo
U-4498
12616740in 13 yr 2 mo
U-4499

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Tirzepatide family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Zepbound (autoinjector): frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 217806 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo